Versions Compared

Key

  • This line was added.
  • This line was removed.
  • Formatting was changed.
https://doi.org/10.1080/10826084.2024.2340975
https://doi.org/10.1186/s42238-024-00234-y
http://www.thieme-connect.com/products/ejournals/abstract/10.1055/a-2264-1047
Book.jpg

elsevier.jpg Cannabis use in the COVID-19 pandemic: Changes in different populations and implications for policy in Linking Neuroscience and Behavior in COVID-19
Created by Adam Zaweel, Isaac Kuk, Soyeon Kim, Bernard Le Foll, Christine Wickens.

https://www.mdpi.com/2076-3425/14/4/356
CaptureSUM.PNG
TandF.png Participant Fraud in Virtual Qualitative Substance Use Research: Recommendations and Considerations for Detection and Prevention Based on a Case Study
Created by Madison Wright, Justin Matheson, Tara Marie Watson, Beth Sproule, Bernard Le Foll, Bruna Brands
The COVID-19 pandemic has accelerated and amplified the use of virtual research methods. While online research has several advantages, it also provides greater opportunity for individuals
https://www.mdpi.com/2076-3425/14/3/246
https://journals.sagepub.com/doi/abs/10.1177/07067437231210796
Can J.jpg
Sage.png The Association Between Self-Reported Anxiety and Retention in Opioid Agonist Therapy: Findings From a Canadian Pragmatic Trial
Created by Anees Bahji, Gabriel Bastien, Paxton Bach, JinCheol Choi, Bernard Le Foll, Ron Lim, Didier Jutras-Aswad & M. Eugenia Socias.
Prescription-type opioid use disorder (POUD) is often accompanied by comorbid anxiety, yet the impact of anxiety on retention in opioid agonist therapy (OAT) is unclear. Therefore, this study investigated…
Clin Pharm.jpg
ASCPT.png Pharmacogenetics of Biochemically Verified Abstinence in an Opioid Agonist Therapy Randomized Clinical Trial of Methadone and Buprenorphine/Naloxone
Created by Intishar Kazi, Meghan Chenoweth, Didier Jutras-Aswad, Keith Ahamad, M. Eugenia Socias, Bernard Le Foll, Rachel Tyndale
Methadone and buprenorphine/naloxone are opioid agonist therapies for opioid use disorder treatment. Genetic factors contribute to individual differences in opioid response…
https://doi.org/10.1186/s12906-023-04312-1
https://doi.org/10.1001/jamanetworkopen.2023.52233
https://doi.org/10.1016/j.brs.2024.01.008
add.v119.2.cover.jpg
Wiley.jpg Prescription psychostimulants for the treatment of amphetamine-type stimulant use disorder: A systematic review and meta-analysis of randomized placebo-controlled trials
Created by Heidar Sharafi, Hamzah Bakouni, Christina McAnulty, Sarah Drouin, Stephanie Coronado-Montoya, Arash Bahremand, Paxton Bach, Nadine Ezard, Bernard Le Foll…
There is currently no standard of care for pharmacological treatment of amphetamine-type stimulant (ATS) use disorder (ATSUD). This systematic review with meta-analysis (PROSPERO CRD42022354492) aimed to pool results from randomized placebo-controlled trials (RCTs) to evaluate efficacy and safety of prescription psychostimulants (PPs) for ATSUD…
https://www.cmaj.ca/content/196/6/E187

...